Does Glucagon-Like Polypeptide 1 improve vascular function and inflammation?

Trial Profile

Does Glucagon-Like Polypeptide 1 improve vascular function and inflammation?

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Liraglutide (Primary) ; Aspirin
  • Indications Embolism and thrombosis; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms GLP-1ADDS
  • Most Recent Events

    • 03 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Nov 2013 Accrual to date is 47% according to United Kingdom Clinical Research Network.
    • 24 Oct 2013 Accrual to date is 43% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top